Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gartisertib - Merck KGaA

Next Previous
X
Search
Drug Profile

Gartisertib - Merck KGaA

Alternative Names: M-4344; MSC2580591A; VRT 1228692; VX-803

Latest Information Update: 26 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck KGaA
  • Class Amides; Amines; Antineoplastics; Fluorobenzenes; Piperazines; Piperidines; Pyrazolones; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 26 Jun 2024 Gartisertib is still in phase I trials for Solid tumours and Lymphoma (Vertex pipeline, June 2024)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in Netherlands (PO)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in Spain (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top